Clinical Trial Search

Primary: Enrollment (150 HIV-infected and 50 HIV-uninfected Pregnant Women Within One Year, With a Minimum of 20 of These Women Having HIV/ZIKV Co-infection by Their End of…

Primary: Number of Solicited Adverse Events — 1; 0; 0; 0 events

Primary: Percentage of Participants With Solicited Local Injection Site Reactions by Severity Within 7 Days After Dose 1 of PIZV or Placebo — 13.3; 30.0; 32.3; 38.7 percentage of…

Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants

Primary: Number of Participants With Adherence to Pediatric Zika Care — 14; 15 Participants

Primary: Number of Subjects With Adverse Events. — 12; 8; 0; 0 participants

Primary: Number of Participants With Solicited Local and General Adverse Events (AEs) — 10; 5; 8; 5 Participants

Primary: Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for All Participants — 15; 22; 10; 18 Participants

Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reaction (ARs)-First Vaccination — 0; 0; 0; 1 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) — 5; 2; 2; 291 Participants

Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) — 86; 164; 183; 163 Participants

Primary: Number of Participants With Serious Adverse Events From Day 0 Through Week 60 — 0; 0 participants

Primary: Percentage of Participants Who Experienced an Adverse Event (AE) up to Day 56 — 92.9; 92.9; 91.7; 62.5 Percentage of Participants — p== 0.2003

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination — 0; 1; 1; 0 participants

Primary: Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection. — 3.00; 5.2; 4.7; 5.0 log10 RNA copies/mL/days

Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants

Primary: Number of Differentially Expressed Genes Between Bitten (Case) Versus Unbitten (Control) Skin for Each of the Three Vector Groups — 18; NA; 1; NA number of…

Primary: Successful Infection of Vector Mosquitoes Following Both Direct and Indirect Feeding on the Blood of Infected Participants

Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants

Primary: Change of Pain Measured by VAS — 5.8; 2.2; 0.6; 1.2 pain intensity

Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42

Primary: AEs Grade 3 or Higher — 0.44; 0.65; 0.63 adverse events

Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants

Primary: Measurement of Change in Early and Late Innate Immune Responses Using Gene Expression and Flow Cytometry in Participants' Skin — 50; 5 % of total dendritic cells

Primary: P. Vivax Blood Collection — 2 Participants

Primary: The Activity of Single Oral Doses of MMV533 (Name of Investigational Medicinal Product) on Clearance of Plasmodium — 42.17; 158.03; 187.57 PRR48=parasite reduction ratio…

Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects

Primary: Infection Success of Vector Mosquitoes — 2; 3 Participants

Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence

Primary: Number of Pregnant Women Vaccinated With RIV4 Versus IIV4 With Adverse Birth Outcomes — 17; 21 Participants — p=<0.0001